Inhibition of anti-tumor immunity by melanoma cell-derived Activin-A depends on STING

Front Immunol. 2024 Jan 18:14:1335207. doi: 10.3389/fimmu.2023.1335207. eCollection 2023.

Abstract

The transforming growth factor-β (TGF-β) family member activin A (hereafter Activin-A) is overexpressed in many cancer types, often correlating with cancer-associated cachexia and poor prognosis. Activin-A secretion by melanoma cells indirectly impedes CD8+ T cell-mediated anti-tumor immunity and promotes resistance to immunotherapies, even though Activin-A can be proinflammatory in other contexts. To identify underlying mechanisms, we here analyzed the effect of Activin-A on syngeneic grafts of Braf mutant YUMM3.3 mouse melanoma cells and on their microenvironment using single-cell RNA sequencing. We found that the Activin-A-induced immune evasion was accompanied by a proinflammatory interferon signature across multiple cell types, and that the associated increase in tumor growth depended at least in part on pernicious STING activity within the melanoma cells. Besides corroborating a role for proinflammatory signals in facilitating immune evasion, our results suggest that STING holds considerable potential as a therapeutic target to mitigate tumor-promoting Activin-A signaling at least in melanoma.

Keywords: STING; activin; cancer; intercellular communication; interferon; knockdown; profiling; scRNA-seq.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activins* / metabolism
  • Animals
  • Melanoma* / immunology
  • Mice
  • Signal Transduction
  • Transforming Growth Factor beta* / metabolism
  • Tumor Escape*
  • Tumor Microenvironment

Substances

  • activin A
  • Activins
  • Transforming Growth Factor beta

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants 31003A_179330 of the Swiss National Science foundation and KFS-4454-02-2018 from Oncosuisse, and by the Anna Fuller Fund award 20495 to DBC.